What we deliver
Biovac started its journey with a big bold step that covered a lot of ground in short space of time. While developing our manufacturing facilities, we have been importing, exporting, packaging, testing and distributing vaccines. Our leap of faith ensured that we delivered the required vaccines to the children’s vaccination program, known as the Expanded Programme on Immunisation, in South Africa and the region.
To ensure continued and seamless delivery; we coordinate supply and demand with offshore suppliers, the South African Department of Health and other partners to ensure that the required vaccines get to where they are needed in all nine provinces of South Africa and a few neighbouring countries. Over 25 million doses of vaccines are delivered a year via our cold and supply chain infrastructure to ensure that the quality of the vaccines at the point of use is guaranteed.
Our Manufacturing Facilities
Our journey to re-establish modern manufacturing capability within the African continent has progressed steadily and significantly. Our license and manufacturing facilities ensure that we continue to constantly deliver quality products. To date, over R600 million has been invested in infrastructure and skills development at Biovac with an economic benefit of over R500m per year to the South African economy. To ensure the manufacture of quality products we have world-class manufacturing infrastructure (upstream processing, downstream processing, formulation, filling, inspection, labelling and packaging), Quality Control laboratories and we have also invested in warehouses with significant cold-storage capacity.
Our sustainable strength, as we progress on our journey lies in our ability to partner with others. We have partnered with research organisations like the University of Cape Town, Council for Scientific and Industrial Research – CSIR, international organisations (World Health Organization – WHO, Program for Applied Technologies in Health – PATH), industry (Sanofi Pasteur of France, , BioFarma of Indonesia, Pfizer of USA) and funding organisations (The Industrial Development Corporation, The Bill and Melinda Gates foundation). Through these partnerships, we have set up the infrastructure described above and are in-sourcing technologies. Biovac has also developed its own vaccine manufacturing technologies and out-licensed these to international partners.
Currently, we employ 250 employees; 85% of whom obtained their tertiary education through universities, trade schools and colleges and the remaining 15% predominantly have a bachelor’s degree or higher qualification. Appropriately skilled and qualified staff are recruited, retained and developed through intensive training programs locally and abroad, the latter with manufacturing partners and international training institutions.